Dr. Keppler received his Ph.D. in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill where he focused on identifying novel ways to inhibit telomerase as an anticancer approach. He completed his postdoctoral training at the National Institute of Environmental Health Sciences in the Laboratory of Molecular Carcinogenesis by helping to further elucidate the roles of chromatin remodeling complexes in steroid receptor-mediated gene expression. With an extensive background in a variety of scientific disciplines, Dr. Keppler joined Metabolon in 2011 and works with the company’s global Pharmaceutical and Biotechnology clients.
Leveraging The Power Of Metabolomics For Microbiome Analysis
Perturbations in the microbiome have been identified as driving factors in several diseases. Microbes interact with their host through biochemical messaging placing metabolomic profiling at the center for helping elucidate the role of the microbiome in human health. Recent advances in this area will be discussed.
Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the microbiome field: